BioMarin Bounces Back as Voxzogo Performs ‘Bigger Than Expected’ in New Indication

BioMarin's Voxzogo Exceeds Expectations in Phase 3 Hypochondroplasia Trial

BioMarin's Voxzogo demonstrated significant efficacy in its Phase 3 CANOPY-HCH-3 study for hypochondroplasia, a rare skeletal disorder. The drug improved annualized growth velocity by 2.33 cm per year versus placebo, exceeding expectations and providing a much-needed win for the company's rare disease portfolio. This positive readout follows recent safety concerns and a failed trial for another therapy. BioMarin plans to file for approval in the third quarter, with analysts anticipating FDA approval. The study also showed improvements in standing height and arm span, though specific data will be released later, offering a potential commercial edge in an underdiagnosed market.

• The Phase 3 CANOPY-HCH-3 study demonstrated Voxzogo's strong efficacy in children with hypochondroplasia, significantly improving annualized growth velocity by 2.33 cm per year compared to placebo. This result was "solidly above" what was observed in its achondroplasia trials and considered "bigger than expected" by analysts. The study also reported significant improvements in key secondary endpoints like standing height and arm span, which have important functional implications, though specific data for these will be presented at a future scientific congress.
• BioMarin intends to file for Voxzogo's approval in hypochondroplasia in the third quarter, with analysts from Stifel and Jefferies expecting FDA approval, deeming it "largely de-risked." Despite the positive data, the market size for hypochondroplasia remains somewhat unclear due to a lower diagnosis rate compared to achondroplasia. However, with increasing genetic testing, diagnostic rates are projected to rise, leading Jefferies to forecast $1 billion in peak sales for both indications combined, though this is considered conservative.
• This positive outcome for Voxzogo is a crucial win for BioMarin, which has recently faced challenges including safety concerns linked to Voxzogo (leading to suspended studies in other indications like Turner syndrome) and a failed Phase 3 trial for its enzyme replacement therapy BMN 401. Expanding into hypochondroplasia could provide a competitive advantage against Ascendis Pharma's Yuviwel, which recently gained FDA approval for achondroplasia, a market where Voxzogo was previously approved and generated $927 million in net revenues last year.

Unpacking the CANOPY-HCH-3 Trial Design and Key Endpoints

A clinical trial of growth hormone (GH) therapy was conducted for patients with skeletal dysplasia accompanying severe short stature caused by hypochondroplasia, along with other conditions including achondroplasia, pseudoachondroplasia, spondyloepiphyseal dysplasia congenita, and Schmid type metaphyseal dysplasia. The study demonstrated significant efficacy of GH therapy on height gain in hypochondroplasia patients over a 1-year treatment period. Growth hormone therapy is identified as a supportive therapy available for hypochondroplasia, though no curative treatment exists for the disease.

Addressing the Significant Unmet Need in Hypochondroplasia Treatment

Hypochondroplasia presents substantial treatment challenges, with no curative therapies currently available and only supportive interventions showing limited efficacy. The therapeutic landscape is characterized by suboptimal outcomes from existing approaches and significant gaps in precision medicine options for this rare skeletal dysplasia.

• Absence of curative treatment options - No precision therapeutic options are currently approved for hypochondroplasia, leaving clinicians with only supportive therapies and limiting patients to symptomatic management rather than addressing underlying pathophysiology

• Limited efficacy of growth hormone therapy - While recombinant human growth hormone (rhGH) shows initial promise with height velocity SDS increasing from -0.51 to +1.58 after one year of treatment, this improvement diminishes over subsequent years and patients fail to achieve adequate final height despite sustained therapy

• Considerable variability in treatment response - Clinical outcomes with current interventions show substantial variation within treated populations, making it difficult to predict which patients will benefit and complicating treatment decision-making for healthcare providers

• Unknown long-term outcomes - The effect of available therapies on final adult height remains unclear, particularly for growth hormone treatment, creating uncertainty about the ultimate clinical benefit of current therapeutic approaches

• Incomplete understanding of disease pathogenesis - The precise contribution of FGFR3 mutations to hypochondroplasia pathophysiology remains elusive, limiting the development of targeted therapeutic interventions and hindering rational drug design efforts

• Lack of evidence for treatment utility - Current evidence gaps include insufficient utility and cost-effectiveness data for hypochondroplasia treatments, making it challenging to establish treatment guidelines and justify therapeutic interventions to healthcare systems

Voxzogo's Safety Profile Across Its Broader Development Program

Published safety and tolerability data demonstrate that Voxzogo (vosoritide) maintains a consistent and favorable safety profile across its studied indications, with most adverse events being mild and self-limiting. The drug has been evaluated in multiple patient populations ranging from infants to adolescents, with comprehensive data from controlled trials, extension studies, and real-world programs spanning up to seven years of treatment experience.

• Injection site reactions represent the most common adverse event, occurring in up to 83.3% of participants across studies, but are typically mild, transient, and self-limiting without requiring treatment discontinuation

• No treatment-related serious adverse events have been reported across the broader development program, including studies in achondroplasia, hypochondroplasia, and thanatophoric dysplasia type 1

• Immunogenicity responses occurred in 42% of patients in phase III studies, with total anti-vosoritide antibodies detected in 25 of 60 treated patients, but showed no apparent impact on growth velocity or drug exposure

• Cardiovascular safety profile is reassuring, with no meaningful correlations observed between vosoritide plasma exposure and changes in heart rate or blood pressure, though isolated cases of transient hypotension have been reported in infants

• Real-world safety data from early access programs in France (62 participants) and Portugal (27 participants) confirm the clinical trial safety profile, with no discontinuations due to adverse events and predominantly mild injection site reactions

• Long-term safety data spanning up to seven years of continuous treatment demonstrate sustained tolerability with no emergence of new safety signals or long-term harms across 464.05 person-years of exposure

• Pediatric safety profile is well-established across age ranges from 3 months to 18 years, with age-appropriate adverse event patterns and no treatment-related deaths reported in controlled studies

• Safety consistency across skeletal dysplasias is demonstrated, with similar tolerability profiles observed in achondroplasia, hypochondroplasia, and thanatophoric dysplasia type 1 patient populations

Vosoritide's Hypochondroplasia Triumph: Expanding the Growth Disorder Franchise

The recent Phase 3 success of BioMarin's Voxzogo (vosoritide) in hypochondroplasia (HCH) represents a pivotal moment for patients and the broader rare disease landscape. Building on its established efficacy in achondroplasia, this positive readout for HCH underscores the profound potential of targeting the fibroblast growth factor receptor 3 (FGFR3) pathway. Vosoritide, a C-type natriuretic peptide analog, effectively counteracts the overactive FGFR3 signaling that impairs endochondral bone growth in these conditions. The observed 2.33 cm/year increase in annualized growth velocity in HCH is not merely a statistical win; it signifies a tangible improvement for children living with a condition for which no approved pharmacological treatments currently exist.

This development carries significant strategic implications. For BioMarin, it solidifies Voxzogo's position as a leading therapy for FGFR3-related skeletal dysplasias, paving the way for a crucial label expansion. This not only diversifies the drug's market but also reinforces the company's expertise and leadership in rare disease therapeutics, especially after recent pipeline setbacks. Furthermore, the success in HCH could catalyze increased diagnostic awareness and efforts for rare skeletal dysplasias, potentially expanding the identified patient population eligible for treatment.

However, several considerations warrant attention. While the short-term safety profile of vosoritide has been reassuring, primarily involving mild injection site reactions, the long-term impact on final adult height, the full spectrum of skeletal deformities, and overall quality of life in HCH patients remains an area for continued investigation. The competitive landscape is also evolving, with other investigational therapies for achondroplasia, such as FGFR1-3 inhibitors, progressing through clinical development. These emerging alternatives could introduce future market dynamics. Moreover, while generally well-tolerated, studies exploring vosoritide in other MAPK pathway disorders have highlighted the need for careful monitoring for specific adverse events like slipped capital femoral epiphyses and genu valgum, should its application broaden further. Ultimately, this HCH data marks a significant step forward in precision medicine for growth disorders, offering new hope while emphasizing the ongoing need for comprehensive, long-term data to fully understand its transformative potential.